Germany updates vaccine policy: meningococcal shots move to adolescents, shingles vaccination expands to high-risk adults from 18. https://t.co/5MHR6RRyDL

Today’s NeuroPulse: • Personalized SCS moves forward as Soin + BIOTRONIK target adaptive neuromodulation • CHMP backs pediatric expansion of Bracco’s Vueway • Nxera reclaims GPR52 schizophrenia program after partner exit https://t.co/WqISE9Szfo

EU seals landmark pharma reform, resetting exclusivity, access rules, and supply obligations across Europe. https://t.co/rjH4jmJKOv

BioMarin to buy Amicus for $4.8B, adding Fabry and Pompe franchises and boosting rare-disease scale. https://t.co/RGWsqMKX5F

Today’s NeuroPulse: fresh capital, early clinical milestones, and regulatory momentum signal neurology’s shift from experimentation to execution across mental health, neurodegeneration, and advanced neurotechnology. https://t.co/8mJc15IjDU

NeuroPulse Today’s Signals @US_FDA clears KPAP. Neuromodulation advances in epilepsy. A Phase 3 miss test neuropsychiatry. Signal over noise in today’s neurology landscape. https://t.co/lKBXdDNsXs

Dutch health leaders aim to address mental health waitlists with group care and early support under a new 2026–2028 agenda. https://t.co/7KLvpuXXKx

ENvue’s UroShield Kit wins NHS Drug Tariff reimbursement, opening nationwide UK access. https://t.co/eiEpJiJefA

ALS commercialization tightens, @GSK doubles down on RNA amplification, and Alzheimer’s real-world evidence goes regulator-grade. Today’s NeuroPulse shows neurology shifting decisively from discovery to execution. https://t.co/MsHEGVGUNp

NeuroPulse Today's signals: • FDA clears adaptive KPAP sleep therapy • NeuroPace files PMA to expand RNS into generalized epilepsy • Phase 3 misses challenges in neuropsychiatric drug development https://t.co/sgoNYB2dsA

Neurology advanced rare pediatric regulation, MS trial setbacks, epilepsy financing, AR-guided neurosurgery, and psychiatric market expansion in Asia, highlighting a sector balancing regulatory rigor. https://t.co/Fw2CT9olfj #NeuroPulse #Neurology #CNS #Neurotech

December deal rush continues as Genentech inks an AI-driven oncology collaboration with Caris Life Sciences worth up to $1.1B, betting on tumor-scale data to fuel next-gen precision cancer drugs. https://t.co/iu2AKGlCf0

Bristol Myers Squibb teams up with Harbour BioMed in a multispecific antibody collaboration worth up to $1.1B, doubling down on next-gen biologics in immunology and oncology. https://t.co/oMNWRdj4o1

Zealand Pharma teams up with OTR Therapeutics in a metabolic disease collaboration worth up to $2.5B, adding oral small-molecule programs alongside its peptide pipeline. https://t.co/3pVfVQA8Jo

Regulatory momentum and reality checks defined neurology today: • FDA accepts CUTX-101 NDA resubmission • Sanofi halts PPMS plans • $55M backs selective mTORC1 epilepsy drug • AR neurosurgery clears the FDA https://t.co/1e8ytVQJ8u #Neurology #Biotech

Yarrow lands ex-China rights to a first-in-class TSHR antibody from China’s GenSci in a deal worth up to $1.37B, betting big on Graves’ disease and thyroid eye disease. https://t.co/GPbY12KwmR

Sobi to acquire Arthrosi for SEK 9.1bn ($950M) with up to SEK 5.3bn ($550M) in milestones, expanding its gout treatment pipeline and inflammation footprint. https://t.co/vuDQgW1QAS

EU seals landmark Pharma Package deal, preserving 8-year data protection, adding new antibiotic incentives, and tightening supply obligations. Biggest overhaul in 20 years. https://t.co/nr5NoXALDR

NeuroPulse Daily: FDA pushes rare disease and ALS programs forward, ISASS backs ReActiv8, @neuroflowlive shows measurable cost impact, and non-surgical BCIs gain fresh capital. The neuro sector is moving fast. https://t.co/FVYdq07UCF

Teleflex to sell anesthesia, urology, and cardiac care units in deals topping $2B, sharpening its focus on higher-growth surgical and interventional markets. https://t.co/jzCxro4aSC